The Trump administration is prioritizing federal approval of psychedelic-assisted therapies for post-traumatic stress disorder, signaling a shift in how the government views these previously banned substances as psychiatric treatments.

The push reflects growing clinical evidence that compounds like MDMA and psilocybin show promise in treating PTSD when administered under professional supervision. Researchers at institutions including Johns Hopkins University and UCSF have documented significant symptom reduction in veterans and trauma survivors using these therapies in controlled settings.

MDMA-assisted therapy has already demonstrated strong results in multiple clinical trials. The Multidisciplinary Association for Psychedelic Studies (MAPS) completed Phase 3 trials showing that 71 percent of participants with severe PTSD experienced clinically meaningful improvement after MDMA-assisted psychotherapy, compared to 29 percent in the placebo group. The FDA granted breakthrough therapy designation to MDMA-assisted therapy for PTSD in 2017, expediting its review process.

Psilocybin research has similarly gained traction. Studies from NYU's Grossman School of Medicine and Imperial College London found that psilocybin-assisted therapy produced sustained reductions in PTSD symptoms, with effects lasting months after treatment completion.

The administration's fast-track approach could accelerate FDA approval timelines and potentially make these therapies available to military service members and veterans within months rather than years. This represents a dramatic policy reversal from decades of restriction on psychedelic research.

Psychiatrists treating PTSD have long noted that conventional medications like SSRIs help only about 30 to 40 percent of patients. Psychedelic-assisted therapies work through different neurological mechanisms, promoting neural plasticity and helping patients process trauma in ways traditional therapy alone cannot achieve.

Veterans advocacy groups support expedited approval, citing the mental health crisis affecting returning